Which inhalational medication is contraindicated for patients with end-stage renal disease?

Which inhalational medication is contraindicated for patients with end-stage renal disease?

• A. Nitrous oxide
• B. Sevoflurane
• C. Halothane
• D. Isoflurane

Answer: (B)

Sevoflurane is the inhalational medication that is typically contraindicated for patients with end-stage renal disease primarily due to its metabolism and the potential accumulation of its metabolites. In patients with compromised renal function, there is an increased risk of the nephrotoxic effects associated with sevoflurane's degradation products. Sevoflurane is metabolized to compounds such as fluoride ions and may lead to further deterioration of renal function in these individuals. In contrast, nitrous oxide, halothane, and isoflurane do not have the same level of contraindication for use in patients with end-stage renal disease. Nitrous oxide, for example, is primarily excreted through the lungs and does not have significant effects on renal function. Halothane and isoflurane also have different metabolic pathways that do not pose the same risks for patients with severe renal impairment. Therefore, the correct choice highlighting the contraindication for patients with end-stage renal disease is sevoflurane.

Sevoflurane is the inhalational medication that is typically contraindicated for patients with end-stage renal disease primarily due to its metabolism and the potential accumulation of its metabolites. In patients with compromised renal function, there is an increased risk of the nephrotoxic effects associated with sevoflurane's degradation products. Sevoflurane is metabolized to compounds such as fluoride ions and may lead to further deterioration of renal function in these individuals.

In contrast, nitrous oxide, halothane, and isoflurane do not have the same level of contraindication for use in patients with end-stage renal disease. Nitrous oxide, for example, is primarily excreted through the lungs and does not have significant effects on renal function. Halothane and isoflurane also have different metabolic pathways that do not pose the same risks for patients with severe renal impairment. Therefore, the correct choice highlighting the contraindication for patients with end-stage renal disease is sevoflurane.